In a patient who has already started atezolizumab (Tecentriq) and bevacizumab (Avastin), is there a role for transarterial embolization such as drug‑eluting bead TACE or bland TACE?

TACE After Starting Atezolizumab-Bevacizumab: Not Recommended as Routine Combination

Current guidelines explicitly state there is insufficient evidence to recommend combining intra-arterial therapy (TACE/TAE) with immunotherapy checkpoint inhibitors like atezolizumab-bevacizumab, and this combination should not be used routinely 1.

Guideline-Based Framework

The 2025 EASL guidelines provide clear direction on this scenario:

• For intermediate-stage HCC with large tumor burden: Intra-arterial therapy (TACE/TAE or SIRT) should NOT be combined with systemic therapy using immunotherapy checkpoint inhibitors due to insufficient evidence 1
• TACE/TAE should be preferred to systemic therapy only when disease is liver-confined AND a selective approach is possible (low tumor size/number, no infiltrative appearance, preserved portal flow) 1
• If already on systemic therapy: The guidelines do not support adding TACE to ongoing immunotherapy

Clinical Decision Algorithm

If Patient Has Progressive Disease on Atezolizumab-Bevacizumab:

1. Assess liver function and performance status

   • Child-Pugh A with good performance status required for any intervention
   • Child-Pugh B or worse: consider best supportive care

2. Evaluate disease pattern:

   • Liver-confined progression with selective targets: Consider switching FROM atezolizumab-bevacizumab TO TACE/TAE as alternative therapy 1
   • Extrahepatic disease or diffuse liver involvement: Continue systemic therapy or switch to second-line systemic options (cabozantinib, regorafenib, ramucirumab if AFP ≥400) 2

3. Do NOT combine both therapies simultaneously - insufficient evidence and not guideline-supported 1

If Patient Has Stable/Responding Disease:

Continue atezolizumab-bevacizumab alone - no role for adding TACE

Important Caveats

The research evidence conflicts with guidelines: Several retrospective studies 3, 4 suggest potential benefit of combining TACE with atezolizumab-bevacizumab, showing improved progression-free survival and response rates. However, these are:

• Retrospective, non-randomized studies from China
• Not yet validated in prospective trials
• Explicitly contradicted by current EASL guidelines stating insufficient evidence 1

One case report 5 describes successful DEB-TACE for hyperprogressive disease during atezolizumab-bevacizumab, allowing resumption of immunotherapy. This represents salvage therapy for a specific complication, not routine combination.

Practical Recommendation

If considering TACE after starting atezolizumab-bevacizumab, you must choose one or the other:

• Stop atezolizumab-bevacizumab → Switch to TACE if disease is liver-confined with selective targets
• Continue atezolizumab-bevacizumab → Do not add TACE

The only exception would be enrollment in a clinical trial specifically studying this combination 6, as the safety and efficacy of concurrent therapy remains unproven in guideline-quality evidence.

For hyperprogressive disease specifically: DEB-TACE may be considered as salvage therapy 5, but this represents treatment of a complication rather than planned combination therapy.